# A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

> **NCT05643794** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 63 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** rozanolixizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05643794
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-21
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-07-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643794, "A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05643794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*